Breaking News Instant updates and real-time market news.

CTRV

ContraVir Pharmaceuticals

$1.12

-0.05 (-4.27%)

11:02
10/13/16
10/13
11:02
10/13/16
11:02

ContraVir jumps after reporting positive interim data for CMX157

ContraVir Pharmaceuticals reported positive interim data for CMX157, the Company's highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study. The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate, TDF, Gilead's (GILD) Viread, in chronically infected hepatitis B, HBV, patients. Patients successfully completed both 5 mg and 10 mg cohorts, and interim data reported below are from 10 HBV-infected patients who completed 14 days of once-a-day oral dosing of 25 mg of CMX157, and two HBV patients treated for 14 days of oral dosing with 300 mg TDF. The CMX157 treated patients showed an average 99% reduction in HBV viral load compared to baseline. Significantly, the observed antiviral activity for CMX157 is comparable to that observed in TDF-treated patients, but at 1/12th the dose. A key goal of this study was to monitor levels of active tenofovir in the blood, exposure to which is a key predictor of off-target side effects. Following oral dosing, levels of CMX157 and active tenofovir in the bloodstream are approximately dose proportional and similar both in chronic HBV patients as well as in an earlier healthy volunteer study. Notably, CMX157 does not appear to break down readily into active tenofovir in the blood in contrast to patients taking Viread. The high levels of circulating tenofovir in subjects taking Viread are consistent with results from earlier published clinical studies of Viread in HIV and HBV patients. These results are significant considering that CMX157 achieved similar antiviral activity compared to Viread while significantly reducing systemic tenofovir exposure. Active tenofovir levels observed in blood following oral dosing of CMX157 are significantly below levels seen for Viread-treated patients, regardless of dose used, which is consistent with CMX157 targeting the liver followed by activation of CMX157 specifically within the liver. This is further supported by the observation that viral load reductions with CMX157 are comparable to Viread despite a significantly lower dose. "We are pleased and excited with these clinical results, as they demonstrate CMX157's great potential in our ongoing effort to develop a cure for HBV," said James Sapirstein, CEO of ContraVir. "The significant viral load reduction and favorable safety at this low dose of CMX157 speaks to the unique liver-targeting mechanism of our drug, which concentrates the antiviral activity of tenofovir in the liver, enabling anti-HBV efficacy at lower doses and minimal drug exposure to other tissues. We believe, based on the data that are being generated, that CMX157 has great potential as a safe and highly potent backbone of combination therapy against HBV." Pharmacokinetic data observed for CMX157 to date in healthy and HBV-infected subjects are similar across the completed Phase 1b and ongoing Phase 2a studies, consistent with the prodrug's site of action and anticipated improved safety profile. CMX157 was earlier found to be safe and well tolerated at daily oral doses of up to 100 mg in healthy volunteers and is presently demonstrating an excellent safety profile at 25 mg dose in the ongoing Phase 2a study in HBV patients. Upon completion of the 4-week dosing regimen and independent safety review, dose escalation is planned to continue at the 50 mg and 100 mg levels, respectively. Similarity of pharmacokinetic profiles observed for CMX157 in healthy and HBV-infected subjects strongly suggests that the remaining 50 mg and 100 mg doses of CMX157 in the ongoing Phase 2a study will also be safe and potentially even more active against HBV. Shares of ContraVir are up 21.44% or 24c to $1.36 per share in morning trading.

  • 01

    Nov

CTRV ContraVir Pharmaceuticals
$1.12

-0.05 (-4.27%)

05/06/16
MAXM
05/06/16
INITIATION
Target $4
MAXM
Buy
ContraVir Pharmaceuticals initiated with a Buy at Maxim
Target $4.

TODAY'S FREE FLY STORIES

MO

Altria Group

$73.65

0.68 (0.93%)

08:02
02/22/17
02/22
08:02
02/22/17
08:02
Earnings
Altria Group backs FY17 adjusted EPS view $3.26-$3.32, consensus $3.31 »

Altria reaffirms its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VFC

VF Corp.

$52.42

-0.26 (-0.49%)

08:02
02/22/17
02/22
08:02
02/22/17
08:02
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MO

Altria Group

$73.65

0.68 (0.93%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Hot Stocks
Breaking Hot Stocks news story on Altria Group »

Altria Group reaffirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

VFC

VF Corp.

$52.42

-0.26 (-0.49%)

08:00
02/22/17
02/22
08:00
02/22/17
08:00
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

, PLKI

Popeyes

$78.73

12.61 (19.07%)

07:56
02/22/17
02/22
07:56
02/22/17
07:56
Recommendations
Restaurant Brands, Popeyes analyst commentary  »

Restaurant Brands…

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

ARGS

Argos Therapeutics

$4.40

-0.3 (-6.38%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Hot Stocks
Breaking Hot Stocks news story on Argos Therapeutics »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Apr

GS

Goldman Sachs

$251.76

1.38 (0.55%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Initiation
Goldman Sachs initiated  »

Goldman Sachs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

RDS.A

Royal Dutch Shell

$52.49

0.29 (0.56%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
Royal Dutch Shell to hold a conference call »

EVP of Gas and Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ACRX

AcelRx

$3.15

0.05 (1.61%)

, CBM

Cambrex

$54.90

0.55 (1.01%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

ACRX

AcelRx

$3.15

0.05 (1.61%)

CBM

Cambrex

$54.90

0.55 (1.01%)

CRIS

Curis

$2.66

-0.02 (-0.75%)

ESPR

Esperion

$24.42

-0.58 (-2.32%)

DVAX

Dynavax

$3.95

-0.05 (-1.25%)

FLXN

Flexion

$19.66

0.43 (2.24%)

GILD

Gilead

$69.29

-0.56 (-0.80%)

CURE

Curative Health Services Inc

$33.80

0.45 (1.35%)

PCRX

Pacira

$44.15

0.45 (1.03%)

NVDQ

Novadaq

$6.76

0.17 (2.58%)

AXON

Axovant Sciences

$12.11

-0.03 (-0.25%)

TSRO

TESARO

$190.27

-0.09 (-0.05%)

EGRX

Eagle Pharmaceuticals

$73.59

-0.53 (-0.72%)

LPNT

LifePoint

$65.15

1.25 (1.96%)

PRTA

Prothena

$55.00

-0.22 (-0.40%)

ABEO

Abeona Therapeutics

$5.25

-0.75 (-12.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 02

    Mar

  • 06

    Mar

  • 17

    Mar

  • 21

    Mar

  • 01

    Apr

  • 27

    Apr

  • 30

    Jun

  • 06

    Oct

MS

Morgan Stanley

$46.56

0.41 (0.89%)

07:54
02/22/17
02/22
07:54
02/22/17
07:54
Initiation
Morgan Stanley initiated  »

Morgan Stanley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:53
02/22/17
02/22
07:53
02/22/17
07:53
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$76.10

2 (2.70%)

07:52
02/22/17
02/22
07:52
02/22/17
07:52
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

SOHO

Sotherly Hotels

$7.04

-0.4 (-5.38%)

07:51
02/22/17
02/22
07:51
02/22/17
07:51
Recommendations
Sotherly Hotels analyst commentary  »

Sotherly Hotels can still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$45.60

-0.02 (-0.04%)

07:49
02/22/17
02/22
07:49
02/22/17
07:49
Initiation
Glaukos initiated  »

Glaukos initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DBD

Diebold

$29.70

-0.4 (-1.33%)

07:48
02/22/17
02/22
07:48
02/22/17
07:48
Initiation
Diebold initiated  »

Diebold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FSLR

First Solar

$36.62

1.78 (5.11%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$126.34

1.07 (0.85%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Hot Stocks
Aetna announces $3.3B accelerated share repurchase »

Aetna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Conference/Events
CFA Society of Washington, D.C. to hold a luncheon discussion »

The CFA Society of…

CSCO

Cisco

$34.13

0.39 (1.16%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Cisco analyst commentary  »

Cisco at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

M

Macy's

$32.29

-0.01 (-0.03%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Macy's analyst commentary  »

Macy's risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$111.07

3.84 (3.58%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Initiation
NVIDIA initiated  »

NVIDIA initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

EYEG

EyeGate

$3.70

2.0601 (125.62%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files $3.29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$66.94

1.02 (1.55%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Hot Stocks
Welltower enters into strategic collaboration with Johns Hopkins Medicine »

Welltower announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 01

    Mar

HD

Home Depot

$145.02

2.02 (1.41%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Recommendations
Home Depot analyst commentary  »

Home Depot guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

AMD

AMD

$14.00

0.87 (6.63%)

07:41
02/22/17
02/22
07:41
02/22/17
07:41
Initiation
AMD initiated  »

AMD initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.